Proton Therapy vs. Traditional Radiation for Head & Neck Cancer: What the Latest Evidence Means for Your Patients

Data from a recent phase 3 trial found that proton therapy improved five-year survival in patients with HPV-associated advanced oropharyngeal cancer compared with standard radiation. The new findings showed a pronounced benefit in patients already at elevated risk for severe side effects going into treatment.

We now have phase 3 data showing improved overall survival with proton therapy in advanced HPV-associated oropharyngeal cancer, not just a toxicity reduction. With our new Proton Center at Speros, we can now include proton therapy as part of the initial treatment conversation.
-George Yang, MD

This adds a new consideration to what has long been a straightforward radiation-first approach, and shifts the relevant question for referring physicians toward which patients would benefit from a proton therapy referral conversation before a treatment plan is finalized.

What Is the Standard Treatment for Oropharyngeal Cancer Today?

Intensity-modulated radiation therapy (IMRT), remains the default approach for most head and neck cancers, including oropharyngeal cancer, and for many patients it works well. Its limitation is that photon beams continue past the tumor on their way through the body, so healthy tissue along the exit pathway still absorbs the radiation. That exposure adds up, particularly in a region as densely packed with sensitive structures as the head and neck.

Proton therapy, sometimes called intensity-modulated proton therapy (IMPT), releases most of its energy at the tumor and stops, avoiding that exit dose.

Does Proton Therapy Improve Survival Outcomes?

The largest head-to-head randomized trial to date comparing IMPT with IMRT, published in December 2025, found a five-year overall survival rate of 90.9% in the proton therapy group compared with 81% in the IMRT group, a 42% reduction in the hazard of death.

Progression-free survival was comparable in the two arms, and disease control at five years looked similar as well.

Toxicity outcomes followed the same pattern. Patients treated with proton therapy had lower rates of severe lymphopenia (76% in IMPT vs. 89% in IMRT), dysphagia (31% vs. 49%), xerostomia (33% vs. 45%) and feeding-tube dependence (26.8% vs. 40.2%).

Study authors described this as the first trial to demonstrate survival benefit for proton therapy in this population, and have characterized the findings as strong enough evidence to support consideration of IMPT as a standard treatment option for appropriately selected patients.

Does This Mean Proton Therapy Is Right for Every Patient?

The UK-based TORPEdo trial, also a randomized phase 3 study, tells a more nuanced story. Investigators found no meaningful difference in patient-reported quality of life, swallowing function or feeding-tube dependence at one year between the two treatments. Modern, quality-controlled IMRT performed better than the research team expected going in.

The data suggests that in a setting where IMRT delivery is tightly quality-assured, the gap between the two approaches narrows considerably. Radiation planning quality, patient anatomy, and disease characteristics all shape how much benefit a given patient stands to gain from proton therapy.

Which Patients Are Most Likely to Benefit from Proton Therapy?

Patients with advanced-stage oropharyngeal cancer, particularly those already at elevated risk for dysphagia, xerostomia, or nutritional decline going into treatment are the strongest candidates for proton therapy.

A patient with a smaller tumor volume and lower baseline risk may receive equivalent outcomes with IMRT delivered by an experienced team. If a patient faces a longer course of treatment near multiple sensitive structures, the case for proton therapy gets stronger.

The best way to make that call is an early conversation about proton therapy with radiation oncology, before a treatment plan is finalized.

What Does Moffitt’s New Proton Center Mean for Referring Providers?

Moffitt's Richard M. Schulze Family Foundation Proton Center at Speros in Land O'Lakes opens to patients this summer, marking Tampa Bay's first proton therapy facility. The center houses a Proteus®️ONE system, giving regional physicians a nearby option for patients who may benefit from proton-based treatment. Dr. George Yang, a radiation oncologist in Moffitt’s Head and Neck and Endocrine Oncology department, will play an important role supporting proton therapy patient discussions and treatment through his clinic at Speros, which opens in August 2026.

A treatment that once required sending a patient several states away is now available locally, which makes an early consult with radiation oncology even more important.

FAQ

How is a patient referred for proton therapy evaluation at Moffitt?

Submit the online physician referral form and indicate the need for a proton therapy consult. Patients will be seen by a specialist to assess tumor staging, location and individual risk factors before recommending proton therapy, IMRT or another approach.

When to Loop In Radiation Oncology

The clearest candidates for a proton therapy evaluation are advanced-stage patients already at elevated risk for treatment-related toxicity, and that determination is easiest to make before a radiation plan is underway. With a proton therapy center now available locally at Moffitt, looping in our radiation oncology specialists early provides the opportunity to weigh which treatment option fits the patient best.